Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase 1 2Phase 3 1

Status

Completed 11Recruiting 10Active not recruiting 3Not yet recruiting 2Withdrawn 1Unknown 1Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 37Colorectal Neoplasms 28Leukemia, Myeloid, Acute 27Neoplasms 26Recurrence 22Neoplasm Metastasis 22Multiple Myeloma 20Advanced Solid Tumors 20Lymphoma, B-Cell 19Breast Neoplasms 17Pancreatic Neoplasms 14Lung Neoplasms 13Glioblastoma 13Carcinoma, Hepatocellular 13Brain Neoplasms 13Lymphoma 12Glioma 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Melanoma 11Hematologic Neoplasms 11Triple Negative Breast Neoplasms 10Squamous Cell Carcinoma of Head and Neck 10Ovarian Neoplasms 10Leukemia 10Advanced Solid Tumor 10Prostatic Neoplasms 9Head and Neck Neoplasms 9Lymphoma, Non-Hodgkin 8Esophageal Neoplasms 8Sarcoma 7

Interventions

Rituximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Not yet recruiting × Epstein-Barr Virus Infections × Clear all
NCT07614282 2026-05-29

Rituximab for PTLD Prevention in Solid Organ Transplant Recipients With EBV DNAemia

Columbia University

Phase 1 Not yet recruiting
28 enrolled

Infections, Epstein-Barr Virus Infections

NCT07557602 2026-04-29

mRNA Vaccine Targeting Epstein-Barr Virus (EBV) in Healthy Young Adults

Vaccine Company, Inc.

Phase 1 Not yet recruiting
45 enrolled

Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡